Open original FDA record ↗Recall record
- FDA identifier
- Z-1065-2019
- Company in FDA record
- Accelerate Diagnostics Inc
- FDA record creation date
- Mar 27, 2019
- First observed by MedTech Watch
- Nov 16, 2026
- Latest observed content change
- Nov 16, 2026
- Recall classification
- Class II
Reason stated in the source
Rare isolates of Enterobacteriaceae may generate a susceptible meropenem Minimum Inhibitory Concentration (MIC) using the affected device and a resistant result by broth microdilution. In order to mitigate any risk associated with these rare isolates, the firm has implemented an Expert Rule that suppresses the meropenem result for isolates that display a profile consistent with those that generated a false-susceptible result. The firm has responded to this risk by implementing a set of suppression rules, in a software update, to prevent incorrect results.
Source facts
- Action
- On 03/13/2017, customers were notified via phone of the potential risk of very major errors with meropenem for systems that have not been equipped with the most recent software update. TB000037, dated 03/16/17, was sent to customers after product launch. TB000082 and TB000083, dated 06/08/2018, were sent to customers that ran patient samples prior to installing the 1.3.1 PSW000012C patch. Starting on 01/25/19, Medical Device Correction notices were sent to customers, which provided a secondary notification of the suppression rules previously provided in TB000082 and TB000083. Customers were asked to do the following: (1) If you have not already done so, please contact customer support to schedule installation of the latest software version on your system. (2) Retrospectively review affected runs, specifically meropenem results. (3) As an interim measure, and until the latest software version is installed, you should review meropenem results obtained with the original software and apply the AST suppression rules (as noted in technical bulletins TB000082 and TB000083) to those results. Customers were asked to compete and return an acknowledgement form to indicate that they have received the correction notice and taken appropriate action. North America Customer Service and Technical Support: Toll free: +1 (888) 586 2939 opt. 4, Direct: +1 (520) 365 3100, Email: Support@axdx.com. EMEA Customer Service and Technical Support:: Direct: +34 93 220 4547, Email: Support.emea@axdx.com.
- Initiated
- 2017-03-13
- Root cause
- Software design
- Terminated
- 2021-05-21
- Distribution
- Worldwide Distribution - US Nationwide North America and Middle East US: TX, IL, TN, GA, CA, AR, MD, VA, Washington DC, IA, PA, NY, WA, and MO. OUS (Foreign): UK, Spain, Italy, and Germany
- Recall number
- Z-1065-2019
- Recall status
- Terminated
- CDRH record ID
- 171153
- FDA record created
- 2019-03-27
- Recall event number
- 82216